A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2011
03/10/2011	US20110061136 Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof
03/10/2011	US20110061114 Novel pro258 gene disruptions, and methods relating thereto
03/10/2011	US20110060605 Methods for predicting responsiveness of a disease or disorder to a receptor tyrosine kinase inhibitor by analysis of mutations in pik3ca
03/10/2011	US20110060290 Stabilized protein compositions
03/10/2011	US20110060130 Neutralizing human anti-igfr antibody
03/10/2011	US20110059901 Compositions and Methods for Treatment of Neoplastic Disease
03/10/2011	US20110059524 Human cdr-grafted antibody and antibody fragment thereof
03/10/2011	US20110059522 Nucleic acids encoding a house dust mite allergen, der p iii, and uses thereof
03/10/2011	US20110059167 Encapsulation of biologically active agents
03/10/2011	US20110059163 Lyophilised antigen composition
03/10/2011	US20110059162 Tannin-chitosan composites
03/10/2011	US20110059150 Coating method
03/10/2011	US20110059142 Encapsulation of biologically active agents
03/10/2011	US20110059140 Extruded rod-shaped devices for controlled release of biological substances to humans and animals
03/10/2011	US20110059138 Compositions and methods for enhancing immune system of felines
03/10/2011	US20110059137 Chemokine gene-modified cells for cancer immunotherapy
03/10/2011	US20110059136 Methods and Compositions for Treating Inflammatory Bowel Disease
03/10/2011	US20110059135 Capsid-Incorporated Antigen for Novel Adenovirus Vaccine
03/10/2011	US20110059134 Prevention of recurrent viral disease
03/10/2011	US20110059133 Ex vivo method for producing a preparation containing cd4+ t cells specific for ebv structural antigens
03/10/2011	US20110059132 Composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
03/10/2011	US20110059131 Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
03/10/2011	US20110059130 Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
03/10/2011	US20110059129 Avian influenza virus vaccine and a method for preparing
03/10/2011	US20110059128 Vaccine composition for vaccinating dogs against canine infectious respiratory disease (cird)
03/10/2011	US20110059127 Use of mutant hiv-1 protease or siv protease as an adjuvant
03/10/2011	US20110059126 Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity
03/10/2011	US20110059125 Zwitterionic immunomodulators for the treatment of asthma and allergy
03/10/2011	US20110059121 Compositions and methods for the prevention and treatment of autoimmune conditions
03/10/2011	US20110059120 Glucan-based vaccines
03/10/2011	US20110059119 Immunogen against campylobacter infection
03/10/2011	US20110059118 Inhibitors of jak
03/10/2011	US20110059116 Laser-based vaccine adjuvants
03/10/2011	US20110059115 Antibody composition exhibiting cellular cytotoxicty due to glycosylation
03/10/2011	US20110059114 Compositions and Methods for the Treatment of Radioresistant Glioma Stem Cells
03/10/2011	US20110059113 Gab2 amplification in melanoma
03/10/2011	US20110059112 Anti-robo4 antibodies and uses therefor
03/10/2011	US20110059111 Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
03/10/2011	US20110059110 Antibody (11c7) anti nogo-a and its pharmaceutical use
03/10/2011	US20110059109 Methods for inducing or enhancing an immune response by administering GITR-binding antibodies
03/10/2011	US20110059108 Methods of modulating apoptosis by administration of relaxin agonists or antagonists
03/10/2011	US20110059107 Antikine antibodies that bind to multiple cc chemokines
03/10/2011	US20110059106 Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
03/10/2011	US20110059105 Tie complex binding proteins
03/10/2011	US20110059104 Apo-2L receptor agonist and CPT-11 synergism
03/10/2011	US20110059103 Future cardiac event biomarkers
03/10/2011	US20110059102 Therapeutic Method Targeting Midkine
03/10/2011	US20110059101 Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
03/10/2011	US20110059100 C/CLP Antagonists And Methods Of Use Thereof
03/10/2011	US20110059099 Treatment of idiopathic thrombocytopenic purpura
03/10/2011	US20110059098 Human Anthrax Toxin Neutralizing Monoclonal Antibodies and Methods of Use Thereof
03/10/2011	US20110059097 MFAP4 as a Marker For Regulatory Cells and Anti-Cancer Cells
03/10/2011	US20110059096 Targeting of Notch3 Receptor Function for Cancer Therapy
03/10/2011	US20110059095 High affinity human antibodies to human protease-activated receptor-2
03/10/2011	US20110059094 Antitumor effects of insulin-responsive dna binding protein-1 (irdbp-1)
03/10/2011	US20110059093 Use of an anti-tau ps422 antibody for the treatment of brain diseases
03/10/2011	US20110059092 Antibodies specific of the beta-amyloid peptides and their uses as diagnostic agents or drugs
03/10/2011	US20110059091 Inhibitors of oncogenic isoforms and uses thereof
03/10/2011	US20110059090 Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
03/10/2011	US20110059089 Protein Markers for Cardiovascular Events
03/10/2011	US20110059088 Protein involved in ovarian cancer
03/10/2011	US20110059087 Il-17 and il-23 antagonists and methods of using the same
03/10/2011	US20110059086 Espfu nucleic acids and proteins and uses thereof
03/10/2011	US20110059085 Staphylococcus aureus-specific antibody preparations
03/10/2011	US20110059084 Agent for treating disease
03/10/2011	US20110059083 Agent for treating disease
03/10/2011	US20110059082 Agent for treating disease
03/10/2011	US20110059081 Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
03/10/2011	US20110059080 Use of an anti-il6 antibody to decrease hepcidin in cancer patients
03/10/2011	US20110059079 Antibody Coformulations
03/10/2011	US20110059078 Anti-ifnar1 antibodies with reduced fc ligand affinity
03/10/2011	US20110059077 Humanized anti-human alpha 9-integrin antibody
03/10/2011	US20110059076 Human serum albumin linkers and conjugates thereof
03/10/2011	US20110059075 Aglycosylated immunoglobulin mutants
03/10/2011	US20110059074 Knowledge-Based Proliferation Signatures and Methods of Use
03/10/2011	US20110059073 Method for treating infectious disease using monoclonal antibodies
03/10/2011	US20110059072 Method for treating cancer using monoclonal antibodies
03/10/2011	US20110059071 Use of cd28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
03/10/2011	US20110059070 Combination therapy for tumoral desease treatment
03/10/2011	US20110059069 Gapr-1 Methods
03/10/2011	US20110059068 Polypeptides involved in immune response
03/10/2011	US20110059067 Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
03/10/2011	US20110059066 PAKs as Modifiers of the CHK Pathway and Methods of Use
03/10/2011	US20110059065 Function and regulation of adamts-1
03/10/2011	US20110059064 Vm23 and Vm24, two scorpion peptides that block human T-lymphocyte potassium channels (sub-type Kv1.3) w/High Selectivity and Decrease the in vivo DTH-responses in Rats
03/10/2011	US20110059063 Antigen binding proteins that bind PAR-2
03/10/2011	US20110059056 Method for the Generation of Genetically Modified Vertebrate Precursor Lymphocytes and Use Thereof for the Production of Heterologous Binding Proteins
03/10/2011	US20110059046 Derivatives of gefitinib
03/10/2011	US20110059041 Vaccine for treatment and prevention of herpes simplex virus infection
03/10/2011	US20110059021 Process for preparing variant of erysipelothrix rhusiopathiae surface protective antigen in e. coli
03/10/2011	US20110059015 Vaccine
03/10/2011	US20110059012 Identification of cd8+ t cells that are cd161hi and/or il18r (alpha) hi and have rapid drug efflux capacity
03/10/2011	US20110059011 Diagnosis and treatment of diseased and damaged tissue
03/10/2011	CA2846746A1 Pcsk9 vaccine
03/10/2011	CA2810119A1 Clec14a inhibitors
03/10/2011	CA2780713A1 Monoclonal antibodies against gonadotropin-releasing hormone receptor
03/10/2011	CA2773234A1 Method of treating eosinophilic esophagitis
03/10/2011	CA2772928A1 Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity
03/10/2011	CA2772921A1 Type 1 interferon diagnostic
03/10/2011	CA2772916A1 Immunogenic compositions including tlr activity modulators

1 ... 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 ... 1823